AstraZeneca (AZ, NASDAQ: AZN) has declared that Shanghai is now its fifth global strategic center, joining the ranks of Cambridge in the UK, Boston and Gethersburg in the United States, and Gothenburg in Sweden. This move is complemented by AstraZeneca’s plan to collaborate with innovative pharmaceutical companies in Shanghai for international business endeavors in 2024. In addition to this strategic expansion, the UK-based pharmaceutical giant has also co-launched a liver cancer early screening and diagnosis initiative with Zhongshan Hospital.
The liver cancer early screening and diagnosis program is spearheaded by Fan Jia, an academician of the Chinese Academy of Sciences and president of Zhongshan Hospital, along with Zhou Jian, the vice president of Zhongshan Hospital. Liver cancer has emerged as the second leading cause of death in China, a country that accounts for nearly half of the global incidences of liver cancer.- Flcube.com
